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Radiation oncology is a rapidly evolving specialty. In analogy 
with the evolution from conventional radiotherapy over 3D 
conformal radiotherapy to intensity modulated radiotherapy 
and volumetric modulated arc therapy there has been a shift 
from the use of anatomical imaging (e.g. CT, MR) to 
functional imaging (e.g. DW-MRI, DCE-MRI) and biological 
imaging (e.g. 18F-FDG PET).  In the current process of 
radiation treatment, the radiobiological response of tumor 
and normal tissue in patients is monitored non-invasively by a 
variety of imaging techniques. Integration of these imaging 
techniques into therapy selection strategies and radiation 
treatment can serve several purposes.  
First, pre-treatment assessments can steer decisions on the 
radiation treatment as such or on the combination with other 
modalities.  
Second, biology-based objective functions can be introduced 
into the radiation treatment planning process by co-
registration of molecular imaging. Relevant radiobiological 
parameters that can be assessed include tumour burden, 
tumour hypoxia, tumour proliferation and tumour 
metabolism. This would allow us to generate customized 
heterogeneous dose distributions with escalated doses to 
tumour areas where radiotherapy resistance mechanisms are 
most prevalent. However, there are some hurdles to 
overcome including the discrepancy between resolution of 
imaging techniques and spatial scale at which radiosensitivity 
is determined and the treatment induced temporal and 
spatial changes in tumor morphology and biology.  
Third, monitoring of temporal and spatial variations in these 
radiotherapy resistance mechanisms early during the course 
of treatment can discriminate responders from non-
responders.  With such information available shortly after the 
start of treatment, modifications can be implemented or the 
radiation treatment plan can be adapted based on the 
biological response pattern.  
In this teaching lecture, some background on the different 
imaging techniques at our disposal for early response 
monitoring wil be given and examples of current applications 
and future prospectives for the further integration of imaging 
in the radiation treatment process will be shown.  
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Uncertainties are still a major challenge in cancer treatment. 
The resulting deviations between planned dose and delivered 
dose need to be minimized. 
The widely used PTV-approach contains several pitfalls. 
Firstly, it is based on a single patient-snapshot in time, 
whereas patient treatment is a dynamic process. Secondly, 
expanding the clinical target volume (CTV) to the planning 
target volume (PTV) always entails an increased dose in the 
organs at risk (OARs). Lastly, it is geared towards geometric 
uncertainties in conjunction with conventional radiotherapy 
and fails in hadron-based therapy. 
For more than a decade, alternate approaches have been an 
active area of research. Thus, there is a multitude of 
methods to be found in literature. While their sheer number 
can be overwhelming, the vast majority fits in two distinct 
categories. On one hand, there are methods that strive to 
control the dose to each element in a volume of interest. On 
the other hand are algorithms, that control the outcome 
metric (e.g. max dose, equivalent uniform dose (EUD)). 
Even though they have considerably different prerequisites, 
strength and weaknesses, they share the common goal of 
target dose escalation and/or improved OAR sparing. This 
also and especially includes non-conventional modalities such 
as hadron-based therapy. Fortunately, with the increasing 
availability of imaging information, the wide-range 
deployment of next generation treatment planning via such 
methods is feasible. 
This teaching lecture will elaborate the general differences 
between both schools of thought, as well as present their 
similarities. It turns out that, upon closer inspection, even a 
quantitative relation can be established. The lecture will also 
include an excursion into algorithm-internal uncertainty 
management. More specifically, it will cover effects that 
arise from finite sample sizes, e.g. due to a limited number 
of images available at the time of planning. The impact of 
treatment fractionation on uncertainty handling will also be 
touched upon. It is the ultimate goal of the lecture to build a 
mind map about different kinds of uncertainties, and how 
they may be tackled. This will be underpinned with an 
exemplaric overview of current literature. 
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Medical images of various modalities are important factors in 
establishing diagnosis and stage of the disease, and are used 
extensively before, during and after radiotherapy of cancer 
patients. However, from treatment planning is commenced 
until radiotherapy has ended, image information is except for 
the dose calculation usually considered only in a very strict 
geometrical sense: To define the target and delineate critical 
structures on planning images, and to realign the patient in 
2, 3, 4 or 6 dimensions according to pretreatment imaging. 
Imaging is currently also used in response evaluation after 
radiotherapy. Both tumor progression and normal tissue 
reactions such as radiological pneumonitis are routinely 
evaluated on CT images after radiotherapy for lung cancer. 
Even though a direct link between radiological observations 
and clinical symptoms is not always evident, any radiological 
finding contain information of the tissue response to 
radiation; a response which might be hard to detect clinically 
due to other co-morbidities, and which might contain 
information on potential emerging toxicity.  
